NovoCure (NVCR) Share-based Compensation (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217.97% |
| Dec 31, 2025 | -32.42% |
| Sep 30, 2025 | 12.16% |
| Jun 30, 2025 | -11.54% |
| Mar 31, 2025 | -52.91% |
| Dec 31, 2024 | 100.09% |
| Sep 30, 2024 | -1.46% |
| Jun 30, 2024 | -6.61% |
| Mar 31, 2024 | 95.46% |
| Dec 31, 2023 | -33.81% |
| Sep 30, 2023 | -19.53% |
| Jun 30, 2023 | -16.23% |
| Mar 31, 2023 | 31.23% |
| Dec 31, 2022 | 13.22% |
| Sep 30, 2022 | 1.87% |
| Jun 30, 2022 | 3.11% |
| Mar 31, 2022 | 11.82% |
| Dec 31, 2021 | -13.04% |
| Sep 30, 2021 | -7.61% |
| Jun 30, 2021 | 47.81% |
| Mar 31, 2021 | -6.96% |
| Dec 31, 2020 | 0.76% |
| Sep 30, 2020 | 7.20% |
| Jun 30, 2020 | 13.37% |
| Mar 31, 2020 | 12.66% |
| Dec 31, 2019 | 2.50% |
| Sep 30, 2019 | 4.41% |
| Jun 30, 2019 | 42.32% |
| Mar 31, 2019 | -9.32% |
| Dec 31, 2018 | 1.55% |
| Sep 30, 2018 | 2.67% |
| Jun 30, 2018 | 19.79% |
| Mar 31, 2018 | 34.05% |
| Dec 31, 2017 | -26.34% |
| Sep 30, 2017 | 13.99% |
| Jun 30, 2017 | 65.97% |
| Mar 31, 2017 | -3.41% |
| Dec 31, 2016 | -16.07% |
| Sep 30, 2016 | -0.20% |
| Jun 30, 2016 | 3.32% |
| Mar 31, 2016 | 21.57% |
| Dec 31, 2015 | 53.28% |
| Sep 30, 2015 | 11.25% |
| Jun 30, 2015 | 45.25% |
| Mar 31, 2015 | 42.68% |
| Dec 31, 2014 | 5.39% |